



**NEWS RELEASE**  
**For Immediate Release**

**IKARIA Announces In-Licensing of “Thyronamine Technology” from the University of California, San Francisco and Oregon Health & Science University**

Ikaria, a Seattle biotechnology company developing novel human therapeutics to meet the unmet needs of critical care patients, announced today that it had completed an exclusive, worldwide license to “Thyronamine Technology” from the University of California, San Francisco (UCSF) and Oregon Health & Science University (OHSU).

Thyronamines are natural products of thyroid hormone biosynthesis and metabolism and are endogenous regulators of energy metabolism. University of California scientist, Dr. Thomas Scanlan, and Oregon Health & Science University scientist, Dr. David Grandy, together discovered a novel thyronamine, 3-iodothyronamine, and characterized its effects on mice, which include induction of hypothermia, or reduced body temperature, and bradycardia, or slowing of the heartbeat.

According to Dr. Scanlan, now Director of the Program in Chemical Biology at OHSU, “It was long known that in addition to the long-term increase in metabolism caused by thyroid hormone, short-term effects, including metabolic depression, also occurred. Thyronamines, as natural metabolites of thyroxin, may account for this action of thyroid hormone.”

Ikaria plans on developing thyronamines as potential treatments for human injuries and diseases in which reducing metabolic demand may prove beneficial. “The thyronamine technology complements our focus on products that have the potential to ‘buy time’ for patients suffering from heart attack or cardiac arrest, or from the trauma of major surgery,” said Dr. Csaba Szabo, Ikaria’s Chief Scientific Officer, adding “we are already profiling the thyronamine new chemical entities in models of human disease in order to select a compound for clinical development”

Ikaria will collaborate with Dr. Scanlan at OHSU to characterize the therapeutic utility of thyronamines. Ikaria is sponsoring thyronamine discovery research in the co-discoverers’ laboratories located in the new Chemical Biology Laboratories in the Department of Physiology & Pharmacology in the School of Medicine at OHSU, and may expand that collaboration to other department faculty in the future.

**About Ikaria**

Ikaria is a Seattle-based biotechnology company focused on developing breakthrough products for critical care. At the forefront of a new research domain in metabolic depression, the company is rapidly pursuing the development of products that would change critical care medicine. The company’s technology is based on early research focused on metabolic control performed by Mark Roth, PhD, investigator at the Fred

Hutchinson Cancer Research Center. For more information on Ikaria, please visit [www.ikaria.com](http://www.ikaria.com).